Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.

30 juli 2026 bijgewerkt door: Swiss Cancer Institute

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. A Phase II Trial.

Melanoma remains a common cancer with rising incidence, and despite significant improvements with immune checkpoint inhibitors (ICIs), clinical outcomes remain heterogeneous. Retrospective analyses across multiple tumor types, including melanoma, suggest that earlier daytime administration of ICIs may enhance therapeutic effectiveness, potentially due to circadian modulation of immune function. A pronounced survival benefit has been observed particularly among female patients receiving earlier infusions. This trial prospectively evaluates whether aligning ICI administration with circadian immune activity can improve outcomes in melanoma and support the development of sex-specific optimization of immunotherapy.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

The introduction of ICIs a decade ago revolutionized the treatment of various malignancies, particularly melanoma. Yet treatment responses are heterogenous and depend on patient characteristics such as sex and age, and tumor characteristics. The relationship between sex and ICI response in melanoma is complex and may be influenced by various factors, including the type of ICI, tumor mutation burden, presence of infiltrating immune cells, microbiome, and concomitant medications affect the immune system's ability to mount antitumor responses. While some retrospective data indicate poorer outcomes for female patients, in other real-world reports female sex is associated with better outcomes. Prospective, sex-stratified clinical studies are necessary to provide a definitive answer and to integrate sex as a critical variable in personalizing melanoma treatment strategies. Temporal variations in antibody responses and anticancer immunity after vaccination have been reported in both humans and mice. Circadian rhythms also remain an important regulator of immune cell activities. The optimal time for inducing adaptive immune responses consistently appears to be situated around or just before behavioral activity; for nocturnal mice this optimal window appears to be the afternoon, while in diurnal humans this may be the early morning. However, the optimal time of day for ICI administration is currently unknown. A retrospective single-center analysis of advanced melanoma patients showed that receiving less than 20% of the ICI infusions after 16h30 was associated with enhanced overall survival. In subgroup analyses, female patients had a significantly longer OS when less than 20% of the treatment was administered after 16h30.

Optimizing the timing of ICI therapy to target the immune system at the time of its highest sensitivity could significantly improve patient outcomes, particularly for female patients, without exposing patients to additional drugs and generating additional toxicity and costs. Given the limitations of retrospective analyses, a prospective randomized trial is essential to obtain results that could potentially change clinical practice.

Studietype

Ingrijpend

Inschrijving (Geschat)

108

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

  • Zwitserland
      • Bellinzona, Zwitserland, 6500
        • Ente Ospedaliero cantonale (EOC)
        • Contact:
        • Hoofdonderzoeker:
          • Cristina Mangas de Arriba, MD
      • Bern, Zwitserland, 3010
        • Inselspital, Bern
        • Hoofdonderzoeker:
          • Berna Özdemir, MD
        • Contact:
      • Geneva, Zwitserland, 1211
        • Hôpitaux Universitaires de Genève HUG
      • Lausanne, Zwitserland, 1011
        • Centre Hospitalier Universitaire Vaudois (CHUV)
        • Contact:
        • Hoofdonderzoeker:
          • Sofiya MD Latifyan
      • Münsterlingen, Zwitserland, 8596
        • Spital Thurgau (Kantonsspital Münserlingen und Frauenfeld)
        • Hoofdonderzoeker:
          • Ioannis Metaxas, MD
        • Contact:
      • Sankt Gallen, Zwitserland, 9007
        • HOCH Health Ostschweiz - Kantonsspital St. Gallen
        • Contact:
        • Hoofdonderzoeker:
          • Tobias Peres, MD
      • Zurich, Zwitserland, 8091
        • Universitätsspital Zürich USZ
    • Canton of Fribourg
      • Fribourg, Canton of Fribourg, Zwitserland, 1708
        • Hfr Fribourg
        • Contact:
        • Hoofdonderzoeker:
          • Bianca Gautron Moura, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Written informed consent according to Swiss law and ICH GCP E6 regulations before registration and prior to any trial specific procedures.
  • Histologically confirmed unresectable cutaneous stage III or stage IV melanoma. Note: Participants with central nervous system (CNS) metastases are eligible.
  • Participants with a previously treated other malignancy are eligible, if the risk of the prior malignancy interfering with either safety or efficacy endpoints is very low.
  • Measurable or evaluable disease.
  • Age ≥ 18 years.
  • Patients deemed suitable for ICI therapy based on the local investigator's clinical assessment.
  • ECOG performance status 0-2.
  • Women of childbearing potential must use effective contraception , not be pregnant or lactating and agree not to become pregnant during trial treatment and until 5 months after the last dose of trial treatment. A negative pregnancy test before inclusion into the trial is required for all women of childbearing potential.
  • Men agree not to donate sperm or to father a child during trial treatment and until 5 months after the last dose of trial treatment.

Exclusion Criteria:

  • Prior treatment with any systemic anti-cancer therapy; with the exception of prior adjuvant anti-PD-1 or BRAF/MEK inhibitor therapy if the time from last dose to recurrence is more than 6 months.
  • Recent treatment (within 28 days prior to first dose) with any experimental drug.
  • Known history of allogeneic organ transplant.
  • Uveal or mucosal melanoma.
  • Receipt of live attenuated vaccine within 28 days prior to first dose.
  • Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information.
  • Known hypersensitivity to trial drug(s) or to any component of the trial drug(s).
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect participant compliance or place the participant at high risk from treatment-related complications.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: ICI Infusions 8-12 h
Participants will be randomized 1:1 to receive standard-of-care ICI therapy in an early (08:00 - 12:00) infusion time window.
Geneesmiddel: Immune Checkpoint Inhibitors

Morning administration of ICI per physician's choice, according to local practice:

Nivolumab (Opdivo®) Monotherapy - 240 mg administered intravenously every 2 weeks (Q2W)

Pembrolizumab (Keytruda®) Monotherapy

- 200 mg administered intravenously every 3 weeks (Q3W)

Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy

  • Induction Phase:

    • Ipilimumab 3 mg/kg intravenously every 3 weeks (Q3W)
    • Nivolumab 1 mg/kg intravenously every 3 weeks (Q3W)
    • Administered for 4 cycles

  • Maintenance Phase:

    • Nivolumab 240 mg administered intravenously every 2 weeks (Q2W) Nivolumab + Relatlimab Fixed-Dose Combination (Opdualag®) Nivolumab 480 mg and relatlimab 160 mg administered intravenously every 4 weeks (Q4W)
Geneesmiddel: Immune Checkpoint Inhibitors

Afternooon administration of ICI per physician's choice, according to local practice:

Nivolumab (Opdivo®) Monotherapy - 240 mg administered intravenously every 2 weeks (Q2W)

Pembrolizumab (Keytruda®) Monotherapy

- 200 mg administered intravenously every 3 weeks (Q3W)

Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy

  • Induction Phase:

    • Ipilimumab 3 mg/kg intravenously every 3 weeks (Q3W)
    • Nivolumab 1 mg/kg intravenously every 3 weeks (Q3W)
    • Administered for 4 cycles

  • Maintenance Phase:

    • Nivolumab 240 mg administered intravenously every 2 weeks (Q2W) Nivolumab + Relatlimab Fixed-Dose Combination (Opdualag®) Nivolumab 480 mg and relatlimab 160 mg administered intravenously every 4 weeks (Q4W)
Actieve vergelijker: ICI Infusions 15-18 h
Participants will be randomized 1:1 to receive standard-of-care ICI therapy in a late (15:00 - 18:00) infusion time window.
Geneesmiddel: Immune Checkpoint Inhibitors

Morning administration of ICI per physician's choice, according to local practice:

Nivolumab (Opdivo®) Monotherapy - 240 mg administered intravenously every 2 weeks (Q2W)

Pembrolizumab (Keytruda®) Monotherapy

- 200 mg administered intravenously every 3 weeks (Q3W)

Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy

  • Induction Phase:

    • Ipilimumab 3 mg/kg intravenously every 3 weeks (Q3W)
    • Nivolumab 1 mg/kg intravenously every 3 weeks (Q3W)
    • Administered for 4 cycles

  • Maintenance Phase:

    • Nivolumab 240 mg administered intravenously every 2 weeks (Q2W) Nivolumab + Relatlimab Fixed-Dose Combination (Opdualag®) Nivolumab 480 mg and relatlimab 160 mg administered intravenously every 4 weeks (Q4W)
Geneesmiddel: Immune Checkpoint Inhibitors

Afternooon administration of ICI per physician's choice, according to local practice:

Nivolumab (Opdivo®) Monotherapy - 240 mg administered intravenously every 2 weeks (Q2W)

Pembrolizumab (Keytruda®) Monotherapy

- 200 mg administered intravenously every 3 weeks (Q3W)

Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy

  • Induction Phase:

    • Ipilimumab 3 mg/kg intravenously every 3 weeks (Q3W)
    • Nivolumab 1 mg/kg intravenously every 3 weeks (Q3W)
    • Administered for 4 cycles

  • Maintenance Phase:

    • Nivolumab 240 mg administered intravenously every 2 weeks (Q2W) Nivolumab + Relatlimab Fixed-Dose Combination (Opdualag®) Nivolumab 480 mg and relatlimab 160 mg administered intravenously every 4 weeks (Q4W)

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Progression-free survival (PFS)
Tijdsspanne: From randomization to Progressive Desease or death, up to 6 years
Progression-free survival (PFS), defined as time from randomization to progression according to local assessment or death. Participants not experiencing an event will be censored at the date of the last available assessment before initiation of a new anti-cancer treatment, if any.
From randomization to Progressive Desease or death, up to 6 years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Overall survival (OS)
Tijdsspanne: From randomization to death, up to 6 year
OS is defined as the time from randomization until death due to any cause. Participants not experiencing an event will be censored at the last date they were known to be alive.
From randomization to death, up to 6 year
Objective response rate (ORR)
Tijdsspanne: At the end of trial treatment, up to 4 years from registration
Objective response rate (ORR) Objective response is defined as any complete response (CR) or partial response (PR) according to local assessment achieved during treatment. Any participant with CR or PR as best observed response during treatment will be considered as a success; otherwise, they will be considered as a failure. Participants without any tumor assessment, or with non-evaluable response (NE) during treatment, will be considered as failures for this endpoint.
At the end of trial treatment, up to 4 years from registration

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Swiss Cancer Institute

Onderzoekers

  • Studie stoel: Berna Özdemir, MD PhD, Insel Gruppe AG, University Hospital Bern

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 september 2026

Primaire voltooiing (Geschat)

1 juni 2030

Studie voltooiing (Geschat)

1 juni 2032

Studieregistratiedata

Eerst ingediend

1 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

1 mei 2026

Eerst geplaatst (Werkelijk)

7 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

31 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

30 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • SCI-004_MELCHRONO

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren